Ikarian Capital’s Bicycle Therapeutics BCYC Stock Holding History

Ikarian Capital’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-203,037	Closed	-$5.18M	–	150
2023 Q2	$5.18M	Sell	203,037 -4,075	-2%	-$94.7K	0.83%	41
2023 Q1	$4.41M	Buy	+207,112	New	+$5.19M	1%	35
2022 Q2	–	Sell	-478,784	Closed	-$21M	–	150
2022 Q1	$21M	Sell	478,784 -134,342	-22%	-$6.27M	2.76%	8
2021 Q4	$37.3M	Buy	613,126 +86,626	+16%	+$4.78M	5.56%	2
2021 Q3	$21.9M	Buy	+526,500	New	+$18.4M	1.54%	14

Other funds holding BCYC

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Ikarian Capital's BCYC Position: Q3 2023 in Review

Ikarian Capital sold out of Bicycle Therapeutics (BCYC) in Q3 2023, closing a stake of 203,037 shares — an estimated $5.18M sold.

Ikarian Capital first reported a position in BCYC in Q3 2021 and held it in 5 quarters. The position peaked at $37.3M in Q4 2021. 101 funds tracked by Wall St. Rank hold BCYC as of Q3 2023.

Ikarian Capital reported no remaining Bicycle Therapeutics position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 203,037 Bicycle Therapeutics shares in Q3 2023, an estimated $5.18M.
Ikarian Capital first reported a position in Bicycle Therapeutics in Q3 2021 and held it in 5 quarters.
Ikarian Capital's Bicycle Therapeutics position peaked at $37.3M in Q4 2021.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.